If you’ve been following developments in cancer immunotherapy closely, you’ve probably heard of programmed death 1 (PD1/PDCD1, also known as CD279) and PDL1 (CD274). Their interaction is at the center of new immune checkpoint-targeting therapies coming out of the pharmaceutical industry, such as Bristol-Myers Squibb’s nivolumab and Merck’s pembrolizumab (1, 5). What are PD1 and PDL1, and… Read article →
Yvonne Collins, PhD is a Technical and Marketing Writer at QIAGEN. She joined the company in 2014 and has been responsible for creating literature for various QIAGEN products including those for gene expression, qPCR, PCR and sample preparation. She received her PhD from Cambridge University in 2014, studying mitochondrial redox signaling.